# Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

> **NCT05806060** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 134 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** VEGFR and TPC
- **DRUG:** TPC

## Key facts

- **NCT ID:** NCT05806060
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806060, "Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05806060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*